In this webinar, Dr. Brady Wu discusses bispecific antibody drugs and their production.
First, he provides a comprehensive overview of the history and development of bispecific antibodies (BsAbs), including their structural biology and strategies like the “common light chain (cLC) approach” to resolve chain mispairing issues. Next, he elaborates on the mechanisms of action of BsAb drugs and challenges in selecting the most active bispecific candidates: currently, over 100 BsAb structural formats exist, with most designed using “knobs-into-holes (KIH)” engineering principles.
Regarding BsAb production, Dr. Wu highlights Biointron‘s expertise in molecular formats like KIH, IgG-scFv, and IgG-VHH, and presents solutions for addressing molecular mispairing and impurity removal during manufacturing. Additionally, he shares case studies and strategies to enhance antibody expression levels and optimize purification processes to meet diverse client requirements.
Finally, Dr. Wu introduces his company’s infrastructure, R&D advantages in bispecific/multispecific antibody fields, and service features. This includes discussions on platform technologies for accelerating therapeutic development and customized solutions for complex antibody engineering challenges.
Key Topics Include:
- Explore the journey of bispecific antibodies from their 1980s origins to cutting-edge products and platforms
- Discuss breakthroughs in the therapeutic area including oncology/immunotherapy
- Analyze the key hurdles in production: structural complexity, stability, and scalable production
- Categories: Cell & Molecular Biology, Clinical Research, Drug Discovery & Development, Pharmacology
- Tags: antibodies, antibody discovery, antibody library, antibody purification, antibody screening, clinical research, drug development, drug discovery, drug testing
Presenters
Brady Wu, PhD
Head of Protein Center
Biointron
Production Partner
Biointron
